Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Investor Presentation (February 2022)
44 slides from Chimeric Therapeutics's investor presentation, Feb 22, 2022
Slide 1: Capital Raising Presentation February 2022
For personal use only CAPITAL RAISING PRESENTATION FEBRUARY 2022
Slide 2: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment presentation, or by any future communications in connection with those advice. The presentation is not intended to be comprehensive or provide all documents and all of those losses and damag
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Rapid Growth Early Positive Clinical Signals For personal use only Fastest growing cell therapy pipeline in Australia Initial positive ph. 1 clinical data in GBM with with 7 novel assets in development dose cohort 4 complete 2H22 Expedited Regulatory Pathway Innovative & Divers
Slide 4: Chimeric Management Team
CHIMERIC MANAGEMENT TEAM GLOBAL EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION For personal use only EXPERIENCE EXPERTISE PROVEN 40+ 25+ 4/5 Years of Cell Therapy Development Of the FDA Approved Experience Programs CAR T Cell Therapies Jennifer Dr Li Elizabeth CHOW Dr Eliot REN TRAUPMAN Chi
Slide 5: World Renowned Advisors and Collaborators
WORLD RENOWNED ADVISORS AND COLLABORATORS For personal use only CELLULAR IMMUNOTHERAPY SCIENTIFIC ADVISORY BOARD RESEARCH COLLABORATORS Chair, Cellular Therapeutics Director, Center for Director Translational Research, Director, Cellular Immune Effector Cell Therapies Cellular Therapy Immunotherapy
Slide 6: Chimeric Therapeutics: Financial Snapshot
CHIMERIC THERAPEUTICS: FINANCIAL SNAPSHOT For personal use only Market Information (as of February 17, 2022) ASX: CHM 52 Week Overview Market Cap $69M As of February 17, 2022 0.40 H/L 0.44c/0.20c 0.35 Shares on Issue 330M 0.30 Board / Management ~30% 0.25 Ownership Pro-forma Cash balance $31.5M List
Slide 7: Chimeric Therapeutics: At IPO vs Now
CHIMERIC THERAPEUTICS: AT IPO VS NOW For personal use only IPO January 2021 July 2021 February 2022 Share Price Following Listing $0.44 Share Price $0.36 Share Price $0.20 Market Cap ~$145m Market Cap ~$119m Market Cap ~$69M Assets: 1 Assets: 2 Assets: 7 Disease Areas: 1 Disease Areas: 5 Disease Are
Slide 8: Advanced Cell Therapy Portfolio and Pipeline
ADVANCED CELL THERAPY PORTFOLIO AND PIPELINE Fast to market development with registration from Phase 2 trial For personal use only 7 Unique Assets 8 Clinical Programs by 2023 10+ Disease Areas
Slide 9: 2021 Key Milestones
2021 KEY MILESTONES Significant achievements and growth in our first year on the ASX For personal use only CREATE AN INDUSTRY ACCELERATE ENSURE TECHNICAL ENHANCE CELL LEADING PORTFOLIO CLINICAL OPERATIONS READINESS THERAPY EXPERTISE DEVELOPMENT CDH17 Licensed from CLTX CAR T GBM Ph. 1 CLTX CAR
Slide 10: CHM 1101 (CLTX CAR T) Encouraging Initial Phase Data
CHM 1101 (CLTX CAR T) Encouraging Initial Phase 1 Data with 2nd cohort complete For personal use only Dose level 1 Dose level 2 (44 X 106 ) CLTX CAR T cells (88 X 106 ) CLTX CAR T cells “This preliminary data is encouraging singular route of intratumoral administration dual routes of intratumoral an
Slide 11: 2022 Key Value Creation Catalysts
2022 KEY VALUE CREATION CATALYSTS EXTENSIVE OPPORTUNITIES FOR VALUE CREATION IN 2022 For personal use only Collaborations and Partnership CLTX CAR T CDH17 CAR T CORE NK • GBM Ph1 Dose Level 3 Completion • Completion of Preclinical Work • Executed License and SRA • GBM Ph1 Dose Level 4 Completion • V
Slide 12: Potential Value Realization Pathways
POTENTIAL VALUE REALIZATION PATHWAYS Cell and gene therapy is the most active investment sector in biotech today For personal use only In the past 18-24 months, 16 of the largest pharmaceutical companies have added cell and gene therapy products to their portfolio ACQUISITION ACQUISITION PARTNERSHIP
Slide 13: Use of Funds & Funding Capacity
USE OF FUNDS & FUNDING CAPACITY Pro-Forma funding of A$58.7m post capital raising and assuming option exercise Company key CLTX and CDH17 programs funded into 2023 and past Phase 1 GBM readout For personal use only PRO-FORMA FUNDING A$M CAPITAL RAISE A$M Existing Cash Balance1 $13.4 CHM 1101 (CLTX C
Slide 14: An Emerging Global Cell Therapy Company
Innovative & Diversified Portfolio Broad Therapeutic Focus 7 novel individualized (autologous) T Development 10+ types of blood cell and off the shelf (allogeneic) NK cancers and solid tumours for extensive For personal use only cell therapies commercial opportunity Extensive Clinical Developm
Slide 15: Offer Overview
For personal use only OFFER OVERVIEW
Slide 16: Capital Raising Overview
CAPITAL RAISING OVERVIEW Chimeric is raising up to approximately A$18.1m via an accelerated non-renounceable entitlement offer For personal use only A 1 for 3.15 accelerated non-renounceable entitlement offer of new shares to existing shareholders to raise up to approximately A$18.1m Offer Structu
Slide 17: Use of Funds
USE OF FUNDS CAPITAL RAISE A$M For personal use only CHM 1101 (CLTX CAR T) Licensing & SRA Fees $4.3 Phase 1 GBM Clinical Trial Expansion $5.1 Phase 1 Solid Tumour Basket Trial $1.0 CHM 1101 Use of Funds $10.4 CHM 2101 (CDH17 CAR T) Licensing and SRA Fees $1.0 Phase 1 $3.4 CHM 2101 Use of Funds $4.4
Slide 18: Key Deliverables
KEY DELIVERABLES For personal use only Use of Program Funds Key Deliverables • Completion of solid tumour preclinical data package $4.3M • COH licensing payments CHM 110 1 $5.1M • Expansion of GBM trial to new sites • Completion of Phase 1A GBM Dose Escalation (CLTX CAR T) • Expansion cohort design
Slide 19: Offer Timetable
OFFER TIMETABLE Indicative capital raising timetable1 Date For personal use only Trading halt and announcement of accelerated non-renounceable entitlement offer Monday, 21 February 2022 Institutional Offer Closes Monday, 21 February 2022 Record date to identify shareholders entitlement to participat
Slide 20: Cell Therapy Overview
For personal use only Cell Therapy Overview
Slide 21: Our Mission
OUR MISSION To Bring the Promise of Cell Therapy to Life For personal use only ‘We can now conclude that We believe that novel CAR-T cells can actually cure patients’ Carl June, MD, University of Pennsylvania cellular therapies have the promise to cure cancer. “These are patients with an abysmal pro
Slide 22: What is Cell Therapy?
What is Cell Therapy? Cell therapy is the transfer of live cells into a patient to help lessen or cure a disease. For personal use only Cell therapy in its most basic form is a blood transfusion. Today’s cell therapies can involve the engineering of live cells to attack specific diseases Chimeric An
Slide 23: Cell Therapy Global Investment
Cell Therapy Global Investment Reflecting the Promise of Cell Therapy For personal use only Global Cell & Gene Therapy Investment (USD) January 2022 Collaborations (USD) $23.1B $18.0B $150M 2021 1 16% from 2020 US Developers 53% increase YoY Upfront $19.9B $3.3B $80M 2020 100% from 2019 European Dev
Slide 24: Building a Cell Therapy Portfolio: T Cells vs NK Cells
BUILDING A CELL THERAPY PORTFOLIO ALTERNATIVE CELL TYPES: T CELLS VS. NK CELLS For personal use only T Cells NK Cells T cells are part of the adaptive immune system- primed to Natural Killer (NK) cells are part of the innate immune response – recognize a specific threat on a foreign cell surface res
Slide 25: Building a Cell Therapy Portfolio: Individualized vs Off the Shelf
BUILDING A CELL THERAPY PORTFOLIO ALTERNATIVE CELL SOURCES: INDIVIDUALIZED VS. OFF THE SHELF For personal use only Individualized • Proven curative efficacy in blood cancers Therapies • Reduced potential for a patient's immune system to attack the cells (Autologous) • Established long term cell pers
Slide 26: Our Strategy
OUR STRATEGY To bring the promise of cell therapy to life For personal use only INNOVATION EXPERIENCE ACCELERATION Develop innovative cell Leverage a team of cell Focus on rapid therapies with the most therapy pioneers and patient access and curative potential for experts asset maximization patients
Slide 27: Chimeric Cell Therapy Portfolio
CHIMERIC CELL THERAPY PORTFOLIO A DIVERSIFIED PIPELINE WITH CUTTING EDGE INNOVATION For personal use only Novel Design T Cells NK Cells Autologous Allogeneic (personal) (off-the-shelf) CLTX CAR T CLTX CAR T CORE-NK Next Gen. CLTX CDH17 Undisclosed (ICT/ ICV) (IV) CDH17 CAR T CORE-NK Platform CAR-NK
Slide 28: Individualized (Autologous) T Cell Programs
For personal use only INDIVIDUALIZED (AUTOLOGOUS) T CELL PROGRAMS
Slide 29: CHM 1101: A First and Best in Class CAR T Cell Therapy
CHM 1101: (CLTX CAR T) A FIRST AND BEST IN CLASS CAR T CELL THERAPY For personal use only First in Class CLTX CAR T Broad Recognition and Binding Potent In Vivo Activity CHM 1101 is a first-in-class CAR T, utilizing In preclinical studies, CHM 1101 was shown to In preclinical studies, CHM 1101 Chlor
Slide 30: CHM 1101 (CLTX CAR T) Ongoing Phase 1 Clinical Trial
CHM 1101 (CLTX CAR T) Ongoing Phase 1 Clinical Trial For personal use only Primary Objective: To assess the safety of CLTX CAR T cells and to determine the maximum tolerated dose schedule and a recommended Phase 2 dosing plan Phase 1 Clinical Trial Design: 4 dose levels and 2 routes of administratio
Slide 31: CHM 1101 Encouraging Initial Phase 1 Data
CHM 1101 (CLTX CAR T) Encouraging Initial Phase 1 Data with 2nd cohort complete For personal use only Dose level 1 Dose level 2 (44 X 106 ) CLTX CAR T cells (88 X 106 ) CLTX CAR T cells “This preliminary data is encouraging singular route of intratumoral administration dual routes of intratumoral an
Slide 32: CLTX CAR T Expansion into Metastatic Melanoma
CLTX CAR T Expansion into Metastatic Melanoma For personal use only Metastatic melanoma is the most serious and life-threatening type of skin cancer Early staining of a melanoma cell line confirms strong MMP-2 309k 1 New cases worldwide each year expression in melanoma and a consistently strong corr
Slide 33: CDH17 CAR T: A First in Class CAR T Cell Therapy
CDH17 CAR T A FIRST IN CLASS CAR T CELL THERAPY For personal use only The first CDH17 CAR T cell therapy in development in the world Broad Applicability to address unmet medical needs in gastrointestinal (GI) cancers such as colorectal and gastric cancer as well as in neuroendocrine CDH17 CAR T tumo
Slide 34: CHM 2101 Promising Preclinical Safety and Efficacy
CHM 2101 (CDH17 CAR T) PROMISING PRECLINICAL SAFETY AND EFFICACY For personal use only CHM 2101 Preclinical Efficacy CHM 2101 Preclinical Safety CHM 2101 CAR T cells demonstrated complete CHM 2101 spared normal cells even when they eradication of tumor cells with no relapse expressed CDH17 1800 In n
Slide 35: Off the Shelf (Allogeneic) Natural Killer Cell Programs
For personal use only OFF THE SHELF (ALLOGENEIC) NATURAL KILLER (NK) CELL PROGRAMS
Slide 36: CORE-NK Platform
CORE-NK PLATFORM Clinically Validated, Off the Shelf, Robust, Enhanced, Natural Killer Cell Platform For personal use only An off the shelf, natural killer cell platform A repeatable platform that can be leveraged to develop unlimited new off the shelf, NK cell therapies Complete Phase 1 clini
Slide 37: CORE-NK Platform Cells
CORE-NK Platform Cells Enhancing the Natural Cancer-Fighting Power of NK cells For personal use only Natural Killer CORE-NK (NK) Cell Platform Cell Natural killer cells are found in our CORE-NK cells are made by bodies normally and are able to activating and expanding recognize and kill cancer cells
Slide 38: CHM 0201 (CORE-NK Platform)
CHM 0201 (CORE-NK Platform) A Clinically Validated, Off the Shelf, Robust, Enhanced, Natural Killer Cell Platform For personal use only CORE-NK Platform Cell CORE-NK Platform Differentiation Derived from a unique feeder cell line Development of master cell bank Demonstrated ability for robust ex
Slide 39: CORE-NK Platform Phase 1 Clinical Trial Complete
CORE-NK PLATFORM PHASE 1 CLINICAL TRIAL COMPLETE For personal use only PATIENT ELIGIBILITY PHASE 1 DOSE ESCALATION BLOOD CANCERS Phase 1 Clinical Trial Dr David Wald, Case Comprehensive Acute Myeloid Leukemia Plasma Cell Myeloma Cancer Center Myelodysplastic Syndromes Acute Lymphoblastic Leukemia St
Slide 40: CHM 0201 Repeatable Technology with Multiple Development Paths
CHM 0201 (CORE-NK PLATFORM) REPEATABLE TECHNOLOGY WITH MULTIPLE DEVELOPMENT PATHS For personal use only 1. CORE-NK Combination Therapy Rapid development in combination therapy Next Generation CORE-NK Platform 2. Further enhancement with next generation technologies CHM 0201 CORE-NK CAR-NK Products P
Slide 41: Key Risks
KEY RISKS Key specific risks associated with Chimeric’s business For personal use only Dependence upon Chimeric is reliant on the continuing operation of the Licence Agreements. A failure of a Licensor or Chimeric to comply with the terms of the Licence Agreement could have a Licence Agreements mate
Slide 42: Key Risks
KEY RISKS Key specific risks associated with Chimeric’s business For personal use only Arrangements with The Company may collaborate with pharmaceutical and life science companies, academic institutions or other partners to complete the development and commercialisation of third-party collaborators
Slide 43: Appendix: References For Potential Value Realization Pathways
Appendix: References For Potential Value Realization Pathways For personal use only ACQUISITIONS 1. https://www.gilead.com/news-and-press/press-room/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion 2. https://www.celgene.com/newsroom/cellular-immunotherapies/celgene-corpo
Slide 44: Contact Information
For personal use only CONTACT INFORMATION Jennifer Chow Chief Executive Officer Chimeric Therapeutics Ltd Cell: +1 908-723-8387 jchow@chimerictherapeutics.com Paul A. Hopper Executive Chairman Chimeric Therapeutics Ltd Cell: +61 406671515 paulhopper@lifescienceportfolio.com 44.
Chimeric Therapeutics — Investor Presentation (February 2022) on 6ix